CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia  by Sanguigni, Valerio et al.
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PD40 Ligand Enhances
onocyte Tissue Factor Expression
nd Thrombin Generation Via Oxidative
tress in Patients With Hypercholesterolemia
alerio Sanguigni, MD,* Domenico Ferro, MD,† Pasquale Pignatelli, MD,† Maria Del Ben, MD,†
ini Nadia, MD,† Mirella Saliola, PHD,† Roberto Sorge, PHD,* Francesco Violi, MD†
ome, Italy
OBJECTIVES We tested the hypothesis that CD40 ligand (CD40L) induces a prothrombotic state by
enhancing oxidative stress.
BACKGROUND Patients with hypercholesterolemia show an ongoing prothrombotic state, but the underlying
mechanism is still unclear.
METHODS Circulating levels of the soluble form of CD40L (sCD40L), prothrombin fragment (F12,
a marker of thrombin generation), and 8-hydroxy-2=-deoxyguanosine (8-OHdG, a marker of
oxidative stress) were measured in 40 patients with hypercholesterolemia and in 20 age- and
gender-matched healthy subjects.
RESULTS Patients with hypercholesterolemia showed significantly higher levels of sCD40L (p  0.005),
8-OHdG (p  0.005), and prothrombin F12 (p  0.005), as compared with control subjects.
Soluble CD40L significantly correlated with 8-OHdG (r 0.85, p 0.0001) and prothrombin
F12 (r 0.83, p 0.0001); a significant correlation between 8-OHdG and prothrombin F12
was also observed (r 0.64, p 0.0001). An in vitro study demonstrated that CD40L-stimulated
monocytes from patients with hypercholesterolemia expressed more tissue factor (TF) and
prothrombin F12 than monocytes from controls; co-incubation of monocytes with either an
inhibitor of NADPH oxidase or an inhibitor of phosphatidylinositol-3-kinase significantly
reduced CD40L-mediated clotting activation. A marked inhibition of CD40L-mediated clotting
activation was also observed in two male patients with hereditary deficiency of gp91 phox, the
central core of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Finally, we
demonstrated that CD40L-mediated clotting activation was significantly inhibited by vitamin C,
a known antioxidant.
CONCLUSIONS This study indicates that in patients with hypercholesterolemia, CD40L over-expresses TF
and increases the thrombin generation rate by an oxidative stress-mediated mechanism that
requires the activation of NADPH oxidase. (J Am Coll Cardiol 2005;45:35–42) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.047the American College of Cardiology Foundation
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apidemiologic and clinical trials have provided clear evi-
ence of a cholesterol role in the occurrence of cardiovas-
ular events (1–3). Accordingly, interventional trials with
tatins have reduced the risk of atherosclerotic complica-
ions in patients with high or average cholesterol levels in
heir serum (4–6). Among the mechanisms through which
holesterol may facilitate the atherosclerotic complication,
he activation of the platelet and clotting system has been
uggested to play a pivotal role. An enhanced platelet
esponse to agonists and elevated urinary excretion of
1-dehydro-thromboxane B2 has been observed in patients
ith hypercholesterolemia (7). Also, enhanced expression of
onocyte tissue factor (TF) and high circulating levels of
rothrombin fragment (F12), a marker of thrombin gen-
ration in vivo, suggested an ongoing prothrombotic state in
his setting (8). The mechanism accounting for increased
From the *Department of Internal Medicine, University of Rome “Tor Vergata,”
ome, Italy; and the †Department of Experimental Medicine and Pathology,
niversity of Rome “La Sapienza,” Rome, Italy.C
Manuscript received July 20, 2004; revised manuscript received September 8, 2004,
ccepted September 14, 2004.hrombin generation in patients with hypercholesterolemia
s still unclear.
The CD40 ligand (CD40L) is a transmembrane protein
xpressed on the surface of lymphocytes, as well as on the
ells of the vascular system, such as endothelial cells, smooth
uscle cells (SMCs), and macrophages (9). CD40L is also
xpressed upon agonist stimulation on platelet surface; then,
t is cleaved and circulates as soluble CD40L (sCD40L)
10). It has been calculated that more than 95% of circulat-
ng sCD40L originates from platelets (11). Upon interac-
ion with its receptor CD40, CD40L elicits inflammatory
nd prothrombotic responses that may favor and accelerate
therosclerotic progression (11). In particular, CD40 co-
ocalizes with TF, a glycoprotein of the extrinsic coagulation
athway that converts factor X to Xa (12) on SMCs within
he atherosclerotic plaque (13); engagement of CD40 with
D40L induces overexpression of TF in SMCs, endothelial
ells, and macrophages (14). Previous studies demonstrated
hat oxidative stress plays a major role in monocyte expres-
ion of TF by promoting nuclear factor (NF)-kappa-B
ctivation (15). On the basis of recent studies showing that
D40L exerts a pro-oxidant effect (16), we speculated that
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CD40L and Oxidative Stress in Hypercholesterolemia January 4, 2005:35–42xidative stress may be involved in CD40L-induced mono-
yte clotting activation. To explore this hypothesis, we
nvestigated the behavior of sCD40L, oxidative stress, and
lotting activation in patients with hypercholesterolemia. In
his report, we show, for the first time, that CD40L
romotes clotting activation by enhancing oxidative stress.
ETHODS
e performed a cross-sectional study comparing 40 pa-
ients with polygenic hypercholesterolemia (21 men and 19
omen; mean age 51.6 years) and 20 gender- and age-
atched subjects with normal cholesterol levels (11 men
nd 9 women; mean age 50.4 years). Both patients and
ontrol subjects were recruited from the same geographic
rea and followed a typical Mediterranean diet. None of the
atients had clinical evidence of cardiovascular disease (as
hown by clinical history, physical examination, and elec-
rocardiogram), diabetes mellitus, or hypertension. Five
atients and seven healthy subjects smoked more than five
igarettes daily. Patients with hypercholesterolemia had not
aken any lipid-lowering agents or antiplatelet drugs in the
revious 30 days. Blood samples mixed with 0.13 mol/l of
odium citrate (ratio 9:1) were obtained between 8 and 9 AM
rom patients and healthy volunteers who had fasted for
2 h and provided their informed consent to participate in
he study. An aliquot of serum was used to measure lipid
rofiles.
ipid profile. Serum levels of total cholesterol and triglyc-
rides were determined using an enzyme-based method.
igh-density lipoprotein cholesterol was measured after
hosphotungstic acid/MgCl2 precipitation of fresh plasma.
ow-density lipoprotein (LDL) cholesterol was calculated
sing the Friedewald formula.
nalysis of sCD40L, F12, and 8-hydroxy-2-deoxyguanosine
8-OHdG). Blood samples were immediately centrifuged at
,000 rpm for 20 min at 4°C, and the supernatant was
ollected and stored at 80°C until measurement. Plasma
evels of sCD40L were measured using a commercial
mmunoassay (Quantikine CD40 ligand, R&D Systems,
inneapolis, Minnesota). Plasma levels of human pro-
hrombin F12 were assayed by an enzyme immunoassay
ased on the sandwich principle (Enzygnost F12, Be-
Abbreviations and Acronyms
F12  prothrombin fragment
LMWH  low-molecular-weight heparin
8-OHdG 8-hydroxy-2-deoxyguanosine
PBMC  peripheral blood mononuclear cell
PBS  phosphate-buffered saline
PI-3-K  phosphatidyl-inositol-3-kinase
sCD40L  soluble CD40 ligand
SMC  smooth muscle cell
TF  tissue factor
X-CGD  X-linked chronic granulomatous diseaseringwerke, Marburg, Germany). 8-OHdG was analyzed tsing a competitive enzyme-linked immunosorbent assay
Bioxytech 8-OHdG-EIA, OXIS Health Products, Port-
and, Oregon) in serum and urine.
p91 phox-deficient patients. X-LINKED CHRONIC GRAN-
LOMATOUS DISEASE (X-CGD) PATIENT DESCRIPTION: X-
inked chronic granulomatous disease, an inherited disorder
haracterized by the absence or deficiency of phagocyte-
icotinamide adenine dinucleotide phosphate (NADPH)
xidase activity, was diagnosed in two male patients (age 33
nd 38 years) by demonstrating the absence or manifest
eficiency of oxidase activity in stimulated neutrophils (17).
diagnosis of X-CGD was subsequently confirmed by the
utation analysis of the CYBB gene encoding the gp91
ubunit of phagocyte-NADPH oxidase (18). Mutation in
atient #1 was identified as a single-base substitution of
uanosine to adenosine at residue 252 in exon 3, resulting in
splicing defect. A deletion of thymine 184 in exon 3 was
dentified for Patient #2, resulting in a frame shift.
n vitro study. MONOCYTE TISSUE FACTOR EXPRESSION
ND MONOCYTE-MEDIATED THROMBIN GENERATION. Pe-
ipheral blood mononuclear cells were isolated from hepa-
inized venous blood of healthy subjects (n  4), patients
ith hypercholesterolemia (n 4), and gp91 phox-deficient
atients (n  2) using an aseptic technique. Platelets were
eparated by centrifugation, once at 140 g and twice at 100
in phosphate-buffered saline (PBS) at room temperature
or 10 min. Peripheral blood mononuclear cells (PBMCs)
ere isolated by centrifugation on lymphoprep (Nyeegard,
slo, Norway) at 1,200 g for 20 min at 20°C. Monocytes,
dentified by May Grunwald Giemsa staining, were between
6% and 22% (mean 19%).
Monocytes (adherent cells) were obtained by incubation
f PBMCs for 90 min at 37°C in a humid atmosphere of 5%
O2 in petri dishes containing Roswell Park Memorial
nstitute (RPMI) 1640, supplemented with 2 mmol/l glu-
amine; lymphocytes (non-adherent cells) were removed by
spiration with a Pasteur pipette and washing of the dishes
ith warm media. The purified monocyte preparation
ontained 85% to 95% of monocytes.
After isolation, cells were washed twice in PBS and pre-
ncubated for 1 h at 2  105 cells/ml in RPMI 1640 at 37°C
% CO2 with 50 and 100 mol/l vitamin C or medium as a
ontrol. Cells were then incubated with 50 ng/ml CD40L
recombinant human CD40L/TNFSF5, R&D Systems) for
h. At the end of the incubation period, the cells and media
ere separated by centrifugation (2,000 g 15 min). The cells
ere washed with Tris-NaCl buffer (0.1 mmol/l NaCl, 0.1%
ovine serum albumin, pH 7.4) then lysed in the same buffer
y adding 15 mmol/l n-octyl-beta-D-glycopyranoside at 37°C
or 30 min. Cell count and trypan blue exclusion were
erformed on cell suspensions after washing. The ELISA for
easuring TF antigen in cell lysate was performed using a
ommercial kit (Imubind Tissue Factor ELISA Kit, American
iagnostica Inc., Greenwich, Connecticut). The lower detec-ion limit is 10 pg/ml. The assay recognizes TF-apo, TF,
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January 4, 2005:35–42 CD40L and Oxidative Stress in Hypercholesterolemiand TF-VII complexes and is designed such that there is no
nterference from other coagulation factors or inhibitors of
rocoagulant activity.
The thrombin generation rate by CD40L-stimulated
onocytes was evaluated in vitro, as previously described
19). For this purpose, a low-molecular-weight heparin
LMWH) anticoagulated blood sample (ratio 1:10) was
aken from healthy volunteers (n  4) and patients with
ypercholesterolemia (n  4). The blood was anticoagu-
ated with LMWH (820 U/ml), because this agent effec-
ively inhibits the formation of thrombin in solution but has
nly a small effect on thrombin generated at and bound to
urfaces. After isolation, monocytes were washed twice in
BS, then incubated (2  105 cells/ml in RPMI 1640 at
7°C 5% CO2) with scalar concentration (5 to 50 ng/ml) of
D40L for 6 h. In another set of experiments, monocytes
ere pre-incubated for 1 h with diphenyliodinium (DPI)
15 mol/l) (NADPH oxidase inhibitor), eicosatetraynoic
cid (ETYA) (35 mol/l) (lipooxygenase inhibitor), wort-
annin (0.1 mol/l) (phosphatidyl-inositol-3-kinase [PI-
-K] inhibitor), vitamin C (50 and 100 mol/l), or medium
s a control before the stimulation with CD40L. The
edium was removed and 1,000 ml overlay heparinized
tandard plasma was added to each well and incubated at
7°C for 24 h. After incubation, samples were harvested,
entrifuged at 4,000 g, and assayed for prothrombin F12
eneration, calculated as the increase in prothrombin F12
evels compared with the value observed in control samples,
hich consisted of heparinized plasma added with CD40L.
ll samples were assayed in duplicate.
igure 1. Plasma levels of soluble CD40 ligand (sCD40L) in patients with
ypercholesterolemia (HC) and healthy subjects (HS). *p 0.0005 for HC
ersus HS.
igure 2. Plasma levels of prothrombin fragment (F12) in patients with8
ypercholesterolemia (HC) and healthy subjects (HS). *p 0.0005 for HC
ersus HS.Endotoxin levels, measured in all reagents according to a
ommercially chromogenic substrate test (Kabi Diagnostica,
tockholm, Sweden), as previously described (20), were
10 pg/ml.
tatistical analysis. The comparisons between variables for
he two independent samples were carried out using the
tudent t test. The two-sample Kolmogorov-Smirnov (Z)
est was used only in case of non-homogeneous variances, as
erified by Levene’s test. The analysis was carried out by
sing Pearson correlation. Data were presented as the mean
alue SD. Statistical significance was defined at p 0.05.
ESULTS
n vivo study. Subjects with hypercholesterolemia had
igher values of total cholesterol (275.33 vs. 171.12 mg/dl,
 0.0005) and LDL cholesterol (183.9 vs. 97.7 mg/dl,
 0.0005) than control subjects. Soluble CD40L plasma
evels were significantly higher in patients with hypercho-
esterolemia than in control subjects (4.18  2.07 ng/ml vs.
.60  0.7 ng/ml, p  0.0005) (Fig. 1); 21 patients with
ypercholesterolemia (53%) versus one control subject had
alues above 3.74 ng/ml (mean  2 SD of control subjects).
he prothrombin F12 plasma levels were significantly
igher in patients with hypercholesterolemia than in control
ubjects (1.91  0.89 nmol/l vs. 1.12  0.49 nmol/l, p 
.0005) (Fig. 2); 17 patients with hypercholesterolemia
43%) versus no control subject had values above 1.86
mol/l (mean  2 SD of control subjects).
The 8-OHdG plasma levels were significantly higher in
atients with hypercholesterolemia than in control subjects
4.74 3.36 ng/ml vs. 1.25 0.92 ng/ml, p 0.005) (Fig.
); 16 patients with hypercholesterolemia (40%) versus one
ontrol subject had values above 3.04 ng/ml (mean 2 SD
f control subjects). In a subgroup of 20 patients with
ypercholesterolemia (10 men and 10 women, mean age
0.8 years), urinary excretion of 8-OHdG was 14.8  5
g/mg creatinine and significantly correlated with serum
evels (r  0.894, p  0.0001) .
Low-density lipoprotein cholesterol was significantly cor-
elated with sCD40L (r  0.62, p  0.0001) (Fig. 4A),
rothrombin F12 (r  0.60, p  0.0001) (Fig. 4B), and
igure 3. Plasma levels of 8-hydroxy-2-deoxyguanosine (8-OHdG) in
atients with hypercholesterolemia (HC) and healthy subjects (HS).
p  0.005 for HC versus HS.-OHdG plasma levels (r  0.59, p  0.0001) (Fig. 4C).
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CD40L and Oxidative Stress in Hypercholesterolemia January 4, 2005:35–42oluble CD40L was significantly correlated with prothrom-
in F12 (r  0.83, p  0.0001) (Fig. 5A) and 8-OHdG
lasma levels (r  0.85, p  0.0001) (Fig. 5B). Prothrom-
in F12 plasma levels were significantly correlated with
-OHdG plasma levels (r  0.64, p  0.0001) (Fig. 5C).
n vitro studies. CLOTTING ACTIVATION BY CD40L. In the
rst part of the in vitro study, we investigated if CD40L, at
concentration relatively close to that found in human
irculation, was able to up-regulate the monocyte expression
f TF. This experiment demonstrated that CD40L (5 to 50
g/ml) as low as 5 ng/ml enhanced TF and thrombin
eneration; a higher rate of clotting activation was found by
ncreasing CD40L concentration (Fig. 6).
igure 4. (A) Correlation between low-density lipoprotein cholesterol
LDL-C) and soluble CD40 ligand (sCD40L). (B) Correlation between
DL-C and prothrombin fragment (F12). (C) Correlation between
DL-C and 8-hydroxy-2-deoxyguanosine (8-OHdG).Next we investigated whether monocytes from four sealthy subjects (2 men and 2 women, ages 44 to 58 years)
nd four patients with hypercholesterolemia (3 men and 1
oman, ages 42 to 59 years) differently expressed TF and
rothrombin F12 upon stimulation with CD40L. Com-
ared with unstimulated monocytes, CD40L enhanced the
ate of thrombin generation in both healthy subjects and
atients with hypercholesterolemia (Fig. 7); however, a
igher concentration of prothrombin F12 was found in
atients compared with healthy subjects. The increased
ormation of prothrombin F12 was likely to be due to
onocyte TF overexpression, as CD40L-stimulated mono-
ytes produced more TF compared with unstimulated
onocytes (Fig. 7); in this case, higher monocyte TF
xpression was detected in patients compared with healthy
igure 5. (A) Correlation between soluble CD40 ligand (sCD40L) and
rothrombin fragment (F12). (B) Correlation between 8-hydroxy-2-
eoxyguanosine (8-OHdG) and sCD40L. (C) Correlation between pro-
hrombin F12 and 8-OHdG.ubjects.
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January 4, 2005:35–42 CD40L and Oxidative Stress in Hypercholesterolemiaxidative stress and clotting activation by CD40L. A
revious study demonstrated that CD40 ligation enhances the
roduction of reactive oxidant species via activation of
ADPH oxidase and PI-3-K (21,22). Incubation of human
onocytes with an inhibitor of NADPH oxidase induced a
ignificant decrease of CD40L-mediated TF expression and
hrombin generation (Fig. 8); TF and thrombin generation
ere also inhibited when monocytes were incubated with a
I-3-K antagonist (Fig. 8). Conversely, no changes in clotting
ctivation were observed when monocytes were incubated with
TYA, an inhibitor of 5-lipoxygenase (Fig. 8).
To further explore the role of NADPH oxidase on
D40L-mediated clotting activation, we repeated the ex-
eriments in two male patients who had X-CGD, a
ereditary deficiency of gp91 phox, the central core of
ADPH oxidase. We demonstrated that, compared with
ontrols, the gp91 phox-deficient patients had much lower
igure 6. Expression of tissue factor (TF) (A) and generation of prothrom-
in fragment (F12) (B) in monocytes taken from healthy subjects (2 men
nd 2 women, mean age 50 years) and stimulated with scalar doses of
D40 ligand (CD40L) (5 to 50 ng/ml). UM  unstimulated monocytes;
M  stimulated monocytes. *p  0.001 for CD40L (5 ng/ml) SM vs.
M. **p 0.0001 for CD40L (25 ng/ml) SM versus UM and CD40L (50
g/ml) SM versus UM.xpression of TF and thrombin generation, thus reinforcing mhe hypothesis that NADPH oxidase has a key role on
D40L-mediated clotting activation (Fig. 9).
In order to investigate whether vitamin C, a known
ntioxidant molecule, influenced CD40L-mediated clotting
ctivation, the experiments were repeated in the presence or
bsence of this vitamin. Co-incubation of CD40L-
timulated monocytes with vitamin C-induced dose-
ependent inhibition of thrombin generation (F:75; p 
.0001) (Fig. 10) and TF expression (F:54; p  0.0001)
Fig. 11). The inhibition of monocyte-dependent pro-
hrombin F12 and TF formation was observed in both
ealthy subjects and patients with hypercholesterolemia.
ISCUSSION
hrombophilia is a frequent occurrence in patients with
ypercholesterolemia and can precipitate cardiovascular
vents in this setting. Thrombophilia is basically charac-
erized by platelet hyperactivation and up-regulation of
F with enhanced thrombin generation (7,8). CD40L
igure 7. Generation of prothrombin fragment (F12) (A) and expression
f tissue factor (TF) (B) by unstimulated monocytes (a) and CD40 ligand
CD40L)-stimulated monocytes taken from healthy subjects (b; n  4) or
atients with hypercholesterolemia (c; n  4). *p  0.0005 for b versus a.
*p  0.003 for c versus b.ay represent an important link between platelet activa-
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CD40L and Oxidative Stress in Hypercholesterolemia January 4, 2005:35–42ion and TF expression. A previous study has demon-
trated that, upon activation, platelets induce TF over-
xpression in whole blood, a phenomenon that was
ignificantly inhibited by an antibody against CD40L
23). In patients with hypercholesterolemia, CD40L is
p-regulated on the platelet surface (24) and may there-
ore represent an important stimulus for TF expression
nd clotting activation. The significant correlation be-
ween sCD40L and prothrombin F12, as shown by the
resent and previous study (25), could indirectly support
his hypothesis but not prove it, because sCD40L has not
een shown to elicit cell activation.
To explore this issue, monocytes from patients and
ealthy subjects were incubated with CD40L to determine
hether a different response to CD40L could account for
he enhanced thrombin generation rate observed in patients
ith hypercholesterolemia. The first novel finding of this
tudy is that CD40L, used in a concentration relatively close
o that found in our patients, exerted a higher procoagulant
ffect in patients with hypercholesterolemia than in control
igure 8. Expression of tissue factor (TF) (A) and generation of prothrom-
in fragment (F12) (B) by monocytes taken from healthy subjects (n 
) and stimulated with CD40 ligand (CD40L) (50 ng/ml) or CD40L plus
iphenyliodonium (DPI) (15 mol/l), eicosatetraynoic acid (ETYA) (35
mol/l), and wortmannin (0.1 mol/l). *p  0.0005 for CD40L (50
g/ml)  DPI (15 M) versus CD40L (50 ng/ml). **p  0.0001 for
D40L (50 ng/ml)  wortmannin (0.1 M) versus CD40L (50 ng/ml).ubjects; such a difference was probably due to a higher Conocyte expression of TF detected in patients compared
ith controls.
Afterward, we investigated whether CD40L enhanced
lotting system activation by oxidative stress, which is
n important intracellular signaling for TF expression. In
act, antioxidants have been reported to inhibit
ipopolysaccharide-induced transcriptional and post-
ranscriptional activation of macrophage TF (26,27). Fur-
hermore, human monocytes exposed to copper-induced
xidative stress showed an enhanced expression of TF,
hich was also inhibited by antioxidants (28). In this study,
e measured plasma levels of 8-OHdG, a reliable marker of
xidative stress (29), and found that, in accordance with a
revious study (30), patients with hypercholesterolemia
howed enhanced oxidative stress. We also found a signif-
cant correlation between 8-OHdG plasma levels and pro-
hrombin F12 plasma levels, suggesting that oxidative
tress could be implicated in clotting system activation. This
nding is consistent with a previous study showing a
ignificant correlation between prothrombin F12 plasma
evels and urinary excretion of isoprostanes, another marker
f oxidative stress, in patients at risk of thrombotic compli-
ations (31). Previous studies have provided evidence that
igure 9. Expression of tissue factor (TF) (A) and generation of prothrom-
in fragment (F12) (B) by 50 ng/ml CD40 ligand-stimulated monocytes
aken from hereditary gp91 deficient-patients (X-GCD; four different
eterminations) or from four healthy subjects (HS) matched for age. *p 
.001 for X-GCD versus HS.D40L exerts a pro-oxidant effect via a mechanism involv-
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January 4, 2005:35–42 CD40L and Oxidative Stress in Hypercholesterolemiang NADPH oxidase (16,21,22). Ha and Lee (22) demon-
trated, in particular, that CD40 ligation uses NADPH
xidase for the production of reactive oxidant species and
equires the activity of PI-3-K. Our data confirm and
xtend these data showing that inhibition of NADPH
xidase and PI-3-K markedly reduces CD40L-mediated
lotting activation by human monocytes. The role of
ADPH oxidase was further reinforced by experiments
onducted in gp91 phox-deficient patients, who showed a
arked decrease of TF and thrombin generation of
D40L-stimulated monocytes compared with control sub-
ects. Finally, we investigated whether vitamin C, a known
ntioxidant, influenced CD40L-mediated clotting activa-
ion. To test this hypothesis, CD40L-induced monocyte-
ependent clotting activation was measured with or without
dding vitamin C; the inhibition of TF and thrombin
igure 10. Generation of prothrombin fragment (F12) by monocytes
timulated with CD40 ligand (CD40L) (50 ng/ml) and CD40L-stimulated
onocytes added with 50 or 100 mol/l of vitamin C in healthy subjects
open bars; n  4) (A) and patients with hypercholesterolemia (solid bars; n
4) (B). *p  0.003 for CD40L (50 ng/ml)-stimulated monocytes added
ith 50mol/l of vitamin C versus CD40L (50 ng/ml)-stimulated monocytes.
*p  0.002 for CD40L (50 ng/ml)-stimulated monocytes added with 100
mol/l of vitamin C versus CD40L (50 ng/ml)-stimulated monocytes.eneration obtained in monocytes incubated with vitamin Cupports the suggestion that oxidative stress may be impli-
ated in clotting system activation by CD40L.
Cross-sectional and prospective studies have shown an
ncrease of sCD40L in patients with acute coronary syn-
romes, and sCD40L is predictive of future cardiovascular
vents in patients with and without cardiovascular events
32–35).
The fact that CD40L exerts a prothrombotic effect via
xidative stress represents novel information that adds
urther insights into CD40L’s role in the progression of
therosclerosis. Our findings suggest that, at the site of the
therosclerotic lesion, CD40L-induced oxidative stress
ould, on the one hand, facilitate accumulation of oxidized
DL within macrophages and, on the other hand, enhance
hrombogenicity of the atherosclerotic plaque.
igure 11. Expression of tissue factor (TF) by monocytes stimulated with
D40 ligand (CD40L) (50 ng/ml) and CD40L-stimulated monocytes
dded with 50 or 100 mol/l of vitamin C in healthy subjects (open bars;
) and patients with hypercholesterolemia (solid bars; B). *p  0.003 for
D40L (50 ng/ml)-stimulated monocytes added with 50 mol/l of
itamin C versus CD40L (50 ng/ml)-stimulated monocytes. **p  0.002
or CD40L (50 ng/ml)-stimulated monocytes added with 100 mol/l of
itamin C versus CD40L (50 ng/ml)-stimulated monocytes.An intriguing implication of this study is that antioxi-
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ctivity. In fact, the in vitro study demonstrated that
D40L-induced clotting system activation could be inhib-
ted using concentrations of vitamin C that may be achieved
n humans after supplementation (36). This hypothesis
hould be investigated by an ad hoc study.
onclusions. This study suggests that clotting system
ctivation in patients with hypercholesterolemia may be
ediated by CD40L. This effect seems to be due to
nhancement of oxidative stress via a NADPH oxidase-
ependent mechanism, thus suggesting a novel mechanism
ccounting for CD40L thrombogenicity.
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